Senores Pharmaceuticals Promoter Espee Therapeutics Pledges 4,00,000 Equity Shares

Senores pharmaceuticals Limited has received a disclosure from promoter group entity Espee Therapeutics LLP regarding the creation of a pledge on 4,00,000 equity shares. The pledge was created on February 13, 2026, and disclosed to the stock exchanges on February 17, 2026, in compliance with SAST Regulations 31(1) and 31(2). Pledge Details The pledge transaction involves specific terms and beneficiaries as outlined in the regulatory filing: Parameter: Details Pledged Shares: 4,00,000 equity shares Percentage of Share Capital: 0.87% Pledgee: Bajaj Finance Limited Date of Pledge Creation: February 13, 2026 Purpose: Collateral for loan taken by Renosen Pharmaceuticals Private Limited Promoter Holdings Structure The disclosure reveals the comprehensive shareholding pattern of promoters and promoter group entities in Senores Pharmaceuticals Limited: Key Promoters: Swapnil Jatin Shah: 35,53,531 shares (7.72% of total share capital) Ashokbhai Vijaysinh Barot: 34,44,869 shares (7.48% of total share capital) Major Promoter Group Entities: Remus Pharmaceuticals Limited: 32,61,744 shares (7.08% of total share capital) Renosen Pharmaceuticals Private Limited: 27,18,719 shares (5.90% of total share capital) Anar Swapnil Shah: 22,94,500 shares (4.98% of total share capital) Aviraj Overseas LLC: 18,95,190 shares (4.12% of total share capital) Regulatory Compliance The disclosure was submitted to both BSE Limited (Scrip Code: 544319) and National Stock Exchange of India Limited (Symbol: SENORES) as mandated under SAST Regulations. Swapnil Jatinbhai Shah, serving as Designated Partner of Espee Therapeutics LLP with DIN 05259821, signed the disclosure documents. Company Information Espee Therapeutics LLP holds a total of 4,95,000 shares in Senores Pharmaceuticals Limited, representing 1.07% of the total share capital. The pledged amount of 4,00,000 shares constitutes approximately 80.81% of Espee Therapeutics LLP's total holding in the company. The entity is registered with LLPIN AAH-8938 and operates from Ahmedabad. Senores Pharmaceuticals Limited successfully concluded its Extra-Ordinary General Meeting (EGM) on January 31, 2026, securing shareholder approval for a significant capital raising initiative through convertible equity warrants. Following the successful EGM, the company has now submitted important amendments and clarifications to the original EGM notice under regulatory compliance requirements. EGM Proceedings and Voting Results The EGM was conducted at 12:30 P.M. through Video Conferencing (VC) and Other Audio-Visual Means (OAVM), with proceedings concluding at 12:55 P.M. The meeting addressed a single special resolution regarding the issuance of convertible equity warrants to the promoter and promoter group. Meeting Details: Information Date & Time: January 31, 2026 at 12:30 P.M. Mode: Video Conferencing/OAVM Duration: 25 minutes (12:30 PM - 12:55 PM) Total Shareholders on Record: 34,881 Cut-off Date: January 24, 2026 Warrant Issuance Approval Shareholders overwhelmingly approved the special resolution for issuing 11,70,000 convertible equity warrants by way of preferential issue on private placement basis to persons belonging to the promoter and promoter group category. The resolution received strong support across all shareholder categories. Voting Results: Votes Percentage Votes in Favor: 17,469,008 96.45% Votes Against: 642,045 3.55% Total Valid Votes: 18,111,053 100.00% Overall Voting Percentage: 39.33% of outstanding shares Regulatory Clarifications and Amendments On February 04, 2026, Senores Pharmaceuticals submitted amendments and clarifications to Item No. 1 of the explanatory statement annexed to the EGM Notice dated January 07, 2026, under Regulation 30 of SEBI LODR Regulations. The company clarified that while the quantum of the proposed issue is less than 5% of the post-issue fully diluted share capital, making Regulation 166A of SEBI ICDR Regulations non-applicable, the company's Articles of Association require obtaining a valuation report from a registered valuer for determining the floor price. Valuation Details: Information Valuation Report Date: January 07, 2026 Registered Valuer: Maitri Valuation Private Limited IBBI Registration No.: IBBI/RV-E/11/2023/184 Recommended Value per Share: ₹812.00 Valuation Method Used: Market Approach (100% weightage) Valuation Methodology The registered valuer considered three valuation approaches: Asset Approach (Net Asset Value Method), Income Approach (Profit Earning Capacity Value Method), and Market Approach (Market Price Method). Since values calculated under the Profit Earning Capacity Value Method and Net Asset Value Method were less than the Market Price Method value, which also represents the Floor Price as per SEBI ICDR Regulations, the valuer assigned nil weightage to the first two methods and 100% weightage to the market approach. Regulatory Compliance Mukesh H. Shah & Co., Company Secretaries, served as the scrutinizer for the voting process, ensuring compliance with Section 108 of the Companies Act, 2013 and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The clarification document was signed by Vinay Kumar Mishra, Company Secretary and Compliance Officer, and made available on the company's website and stock exchange platforms for stakeholder access. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.